Merit Medical Systems financials
$87.87+1.00%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Quarter | Q2 '26 Jun 30 | Q1 '26 Mar 31 | Q4 '25 Dec 31 | Q3 '25 Sep 30 | Q2 '25 Jun 30 | Q1 '25 Mar 31 | Q4 '24 Dec 31 | Q3 '24 Sep 30 | Q2 '24 Jun 30 | Q1 '24 Mar 31 | Q4 '23 Dec 31 | Q3 '23 Sep 30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $418.8M | $381.9M | $393.9M | $384.2M | $382.5M | $355.4M | $355.2M | $339.8M | $338.0M | $323.5M | $324.5M | $315.2M |
| Gross profit | $215.2M | $184.8M | $195.4M | $186.4M | $184.5M | $172.0M | $173.0M | $157.5M | $161.1M | $151.7M | $150.5M | $142.2M |
| Gross margin | 51.4% | 48.4% | 49.6% | 48.5% | 48.2% | 48.4% | 48.7% | 46.4% | 47.7% | 46.9% | 46.4% | 45.1% |
| Operating income | $60.4M | $44.2M | $54.2M | $42.6M | $46.9M | $41.0M | $36.6M | $37.3M | $45.9M | $35.9M | $33.6M | $35.1M |
| Net income | $38.8M | $41.0M | $38.0M | $27.8M | $32.6M | $30.1M | $27.9M | $28.4M | $35.7M | $28.2M | $27.6M | $25.8M |
| Net margin | 9.3% | 10.7% | 9.6% | 7.2% | 8.5% | 8.5% | 7.9% | 8.4% | 10.6% | 8.7% | 8.5% | 8.2% |
| Diluted EPS | $0.65 | $0.68 | $0.63 | $0.46 | $0.54 | $0.49 | $0.46 | $0.48 | $0.61 | $0.48 | $0.47 | $0.44 |
| EBITDA | $91.4M | $74.7M | $85.7M | $73.9M | $77.9M | $70.3M | $65.2M | $63.7M | $70.0M | $59.5M | $31.4M | $59.7M |
| Operating cash flow | $69.3M | $40.7M | $98.5M | $75.0M | $83.3M | $40.6M | $68.7M | $47.3M | $68.5M | $36.2M | $64.4M | $48.9M |
| Free cash flow | $51.9M | $24.7M | $74.0M | $52.5M | $69.6M | $19.5M | $65.3M | $38.0M | $57.9M | $24.5M | $57.3M | $40.3M |
| Diluted shares | 60.0M | 60.0M | 60.0M | 59.9M | 60.6M | 61.3M | 60.6M | 59.5M | 58.7M | 58.6M | 58.4M | 58.4M |
Balance sheet
| Period end | Jun 30 | Mar 31 | Dec 31 | Sep 30 | Jun 30 | Mar 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $448.7M | $488.1M | $446.4M | $392.5M | $341.8M | $395.5M |
| Short-term investments | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total debt | $736.3M | $735.2M | $734.0M | $732.9M | $731.8M | $730.7M |
| Total assets | $2.86B | $2.72B | $2.69B | $2.63B | $2.59B | $2.47B |
| Total liabilities | $1.18B | $1.09B | $1.10B | $1.10B | $1.10B | $1.04B |
| Shareholders' equity | $1.68B | $1.63B | $1.58B | $1.53B | $1.49B | $1.43B |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology